SABCS 2023 Breast Cancer Highlights - NATALEE, MONARCH-3, INAVO120, TROPION-Breast01

แชร์
ฝัง
  • เผยแพร่เมื่อ 7 ม.ค. 2024
  • In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo:
    - NATALEE Update - Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis
    - MONARCH 3 - Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2- Advanced Breast Cancer
    - INAVO120 - Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2- Locally Adv/Metastatic Breast Cancer
    - TROPION-Breast01 - Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2- Breast Cancer
    #SABCS #Endocrine #Sensitive #Breast #Cancer #2023 #oncology #oncbrothers
    Website: www.oncbrothers...
    Twitter: / oncbrothers
    Contact us at info@oncbrothers.com

ความคิดเห็น • 2

  • @sulfasalazina
    @sulfasalazina 7 หลายเดือนก่อน

    Thanks for this nice presentation

  • @WATERBURG
    @WATERBURG 7 หลายเดือนก่อน

    dr Rugo!!!!!!!